-
3
-
-
84891486553
-
-
T.J. Dougherty, M.J. Pucci, Springer New York
-
L.G. Czaplewski, N.R. Stokes, S. Ruston, and D.J. Haydon T.J. Dougherty, M.J. Pucci, Antibiotic Discovery and Development 2012 Springer New York
-
(2012)
Antibiotic Discovery and Development
-
-
Czaplewski, L.G.1
Stokes, N.R.2
Ruston, S.3
Haydon, D.J.4
-
7
-
-
0032987247
-
-
Y. Ohashi, Y. Chijiiwa, K. Suzuki, K. Takahashi, H. Nanamiya, T. Sato, Y. Hosoya, K. Ochi, and F. Kawamura J. Bacteriol. 181 1999 1348
-
(1999)
J. Bacteriol.
, vol.181
, pp. 1348
-
-
Ohashi, Y.1
Chijiiwa, Y.2
Suzuki, K.3
Takahashi, K.4
Nanamiya, H.5
Sato, T.6
Hosoya, Y.7
Ochi, K.8
Kawamura, F.9
-
8
-
-
52249120794
-
-
D.J. Haydon, N.R. Stokes, R. Ure, G. Galbraith, J.M. Bennett, D.R. Brown, P.J. Baker, V.V. Barynin, D.W. Rice, S.E. Sedelnikova, J.R. Heal, J.M. Sheridan, S.T. Aiwale, P.K. Chauhan, A. Srivastava, A. Taneja, I. Collins, J. Errington, and L.G. Czaplewski Science 321 2008 1673
-
(2008)
Science
, vol.321
, pp. 1673
-
-
Haydon, D.J.1
Stokes, N.R.2
Ure, R.3
Galbraith, G.4
Bennett, J.M.5
Brown, D.R.6
Baker, P.J.7
Barynin, V.V.8
Rice, D.W.9
Sedelnikova, S.E.10
Heal, J.R.11
Sheridan, J.M.12
Aiwale, S.T.13
Chauhan, P.K.14
Srivastava, A.15
Taneja, A.16
Collins, I.17
Errington, J.18
Czaplewski, L.G.19
-
9
-
-
57749110369
-
-
L.G. Czaplewski, I. Collins, E.A. Boyd, D. Brown, S.P. East, M. Gardiner, R. Fletcher, D.J. Haydon, V. Henstock, P. Ingram, C. Jones, C. Noula, L. Kennison, C. Rockley, V. Rose, H.B. Thomaides-Brears, R. Ure, M. Whittaker, and N.R. Stokes Bioorg. Med. Chem. Lett. 19 2009 524
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 524
-
-
Czaplewski, L.G.1
Collins, I.2
Boyd, E.A.3
Brown, D.4
East, S.P.5
Gardiner, M.6
Fletcher, R.7
Haydon, D.J.8
Henstock, V.9
Ingram, P.10
Jones, C.11
Noula, C.12
Kennison, L.13
Rockley, C.14
Rose, V.15
Thomaides-Brears, H.B.16
Ure, R.17
Whittaker, M.18
Stokes, N.R.19
-
10
-
-
77952728317
-
-
D.J. Haydon, J.M. Bennett, D. Brown, I. Collins, G. Galbraith, P. Lancett, R. Macdonald, N.R. Stokes, P.K. Chauhan, J.K. Sutariya, N. Nayal, A. Srivastava, J. Beanland, R. Hall, V. Henstock, C. Noula, C. Rockley, and L. Czaplewski J. Med. Chem. 53 2010 3927
-
(2010)
J. Med. Chem.
, vol.53
, pp. 3927
-
-
Haydon, D.J.1
Bennett, J.M.2
Brown, D.3
Collins, I.4
Galbraith, G.5
Lancett, P.6
Macdonald, R.7
Stokes, N.R.8
Chauhan, P.K.9
Sutariya, J.K.10
Nayal, N.11
Srivastava, A.12
Beanland, J.13
Hall, R.14
Henstock, V.15
Noula, C.16
Rockley, C.17
Czaplewski, L.18
-
11
-
-
84891483813
-
-
International Patent, publication WO2007/107758.
-
Brown, D.R. Collins, I. Czaplewski, L.G. Haydon, D.J. International Patent, publication WO2007/107758.
-
-
-
Brown, D.R.1
Collins, I.2
Czaplewski, L.G.3
Haydon, D.J.4
-
12
-
-
84872020106
-
-
N.R. Stokes, N. Baker, J.M. Bennett, J. Berry, I. Collins, L.G. Czaplewski, A. Logan, R. Macdonald, L. MacLeod, H. Peasley, J.P. Mitchell, N. Nayal, A. Yadav, A. Srivastava, and D.J. Haydon Antimicrob. Agents Chemother. 57 2013 317
-
(2013)
Antimicrob. Agents Chemother.
, vol.57
, pp. 317
-
-
Stokes, N.R.1
Baker, N.2
Bennett, J.M.3
Berry, J.4
Collins, I.5
Czaplewski, L.G.6
Logan, A.7
Macdonald, R.8
Macleod, L.9
Peasley, H.10
Mitchell, J.P.11
Nayal, N.12
Yadav, A.13
Srivastava, A.14
Haydon, D.J.15
-
13
-
-
84891484402
-
-
Clinical and Laboratory Standards Institute. CLSI Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
-
Clinical and Laboratory Standards Institute. CLSI Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
-
-
-
-
15
-
-
28844488672
-
-
N.R. Stokes, J. Sievers, S. Barker, J.M. Bennett, D.R. Brown, I. Collins, V.M. Errington, D. Foulger, M. Hall, R. Halsey, H. Johnson, V. Rose, H.B. Thomaides, D.J. Haydon, L.G. Czaplewski, and J. Errington J. Biol. Chem. 280 2005 39709
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 39709
-
-
Stokes, N.R.1
Sievers, J.2
Barker, S.3
Bennett, J.M.4
Brown, D.R.5
Collins, I.6
Errington, V.M.7
Foulger, D.8
Hall, M.9
Halsey, R.10
Johnson, H.11
Rose, V.12
Thomaides, H.B.13
Haydon, D.J.14
Czaplewski, L.G.15
Errington, J.16
-
16
-
-
84891485963
-
-
Groups of healthy adult male Balb/c mice received compounds by intravenous (IV) or oral (PO) administration at a dose level of 3 mg/kg. In all cases the dose volume was 5 mL/kg. Compounds were formulated in 10% dimethyl sulfoxide (DMSO), 40% tetraethylene glycol (TEG), and 20% 2-hydroxypropyl- β-cyclodextrin (HPβCD) in water (final). At various time points, samples of blood were collected for analysis. Three animals were used for each time point. Total plasma concentrations of compounds were measured by LC-MS/MS and pharmacokinetic parameters were calculated using Win-Nonlin.
-
Groups of healthy adult male Balb/c mice received compounds by intravenous (IV) or oral (PO) administration at a dose level of 3 mg/kg. In all cases the dose volume was 5 mL/kg. Compounds were formulated in 10% dimethyl sulfoxide (DMSO), 40% tetraethylene glycol (TEG), and 20% 2-hydroxypropyl- β-cyclodextrin (HPβCD) in water (final). At various time points, samples of blood were collected for analysis. Three animals were used for each time point. Total plasma concentrations of compounds were measured by LC-MS/MS and pharmacokinetic parameters were calculated using Win-Nonlin.
-
-
-
-
17
-
-
84891488509
-
-
2 at ambient temperature for 48 h.
-
2 at ambient temperature for 48 h.
-
-
-
-
18
-
-
84863341292
-
-
C.M. Tan, A.G. Therien, J. Lu, S.H. Lee, A. Caron, C.J. Gill, C. Lebeau-Jacob, L. Benton-Perdomo, J.M. Monteiro, P.M. Pereira, N.L. Elsen, J. Wu, K. Deschamps, M. Petcu, S. Wong, E. Daigneault, S. Kramer, L. Liang, E. Maxwell, D. Claveau, J. Vaillancourt, K. Skorey, J. Tam, H. Wang, T.C. Meredith, S. Sillaots, L. Wang-Jarantow, Y. Ramtohul, E. Langlois, F. Landry, J.C. Reid, G. Parthasarathy, S. Sharma, A. Baryshnikova, K.J. Lumb, M.G. Pinho, S.M. Soisson, and T. Roemer Sci. Transl. Med. 4 2012 126
-
(2012)
Sci. Transl. Med.
, vol.4
, pp. 126
-
-
Tan, C.M.1
Therien, A.G.2
Lu, J.3
Lee, S.H.4
Caron, A.5
Gill, C.J.6
Lebeau-Jacob, C.7
Benton-Perdomo, L.8
Monteiro, J.M.9
Pereira, P.M.10
Elsen, N.L.11
Wu, J.12
Deschamps, K.13
Petcu, M.14
Wong, S.15
Daigneault, E.16
Kramer, S.17
Liang, L.18
Maxwell, E.19
Claveau, D.20
Vaillancourt, J.21
Skorey, K.22
Tam, J.23
Wang, H.24
Meredith, T.C.25
Sillaots, S.26
Wang-Jarantow, L.27
Ramtohul, Y.28
Langlois, E.29
Landry, F.30
Reid, J.C.31
Parthasarathy, G.32
Sharma, S.33
Baryshnikova, A.34
Lumb, K.J.35
Pinho, M.G.36
Soisson, S.M.37
Roemer, T.38
more..
-
19
-
-
84891494627
-
-
In addition to the steps shown explicitly, phenyl oxazole 21 was prepared via Suzuki coupling of the appropriate oxazolyl bromide. Compounds 16, 17, 19 and 22 were prepared from the corresponding oxazolyl bromide by means of Stille coupling and, where required, subsequent Pd-catalysed hydrogenation. 5-Chloro-and 5-iodo-oxazoles 25 and 27 were synthesised in a manner analogous to 26 using N-chlorosuccinimide (NCS) or N-iodosuccinimide (NIS) in place of N-bromosuccinimide (NBS). Trifluoromethyl derivative 28 was prepared by treatment of the appropriate oxazolyl iodide intermediate with methyl 2,2-difluoro-2-(fluorosulfonyl)acetate and copper(I) iodide in HPMA and N,N-dimethylformamide (DMF).
-
In addition to the steps shown explicitly, phenyl oxazole 21 was prepared via Suzuki coupling of the appropriate oxazolyl bromide. Compounds 16, 17, 19 and 22 were prepared from the corresponding oxazolyl bromide by means of Stille coupling and, where required, subsequent Pd-catalysed hydrogenation. 5-Chloro-and 5-iodo-oxazoles 25 and 27 were synthesised in a manner analogous to 26 using N-chlorosuccinimide (NCS) or N-iodosuccinimide (NIS) in place of N-bromosuccinimide (NBS). Trifluoromethyl derivative 28 was prepared by treatment of the appropriate oxazolyl iodide intermediate with methyl 2,2-difluoro-2-(fluorosulfonyl)acetate and copper(I) iodide in HPMA and N,N-dimethylformamide (DMF).
-
-
-
-
20
-
-
84891490971
-
-
Enantiomers 48 and 3 were separated from a 1 g sample of the racemic mixture 36 using a CHIRALPAK® AD-H, (250 × 30) mm, 5 μm 5 122 column with a n-hexane/EtOH/MeOH (80:10:10 v/v/v) mobile phase.
-
Enantiomers 48 and 3 were separated from a 1 g sample of the racemic mixture 36 using a CHIRALPAK® AD-H, (250 × 30) mm, 5 μm 5 122 column with a n-hexane/EtOH/MeOH (80:10:10 v/v/v) mobile phase.
-
-
-
-
21
-
-
84891491081
-
-
The kinetic solubility of the compounds was measured using a turbidimetric method. A series of doubling dilutions of compounds were prepared in neat DMSO. Five microlitre samples were diluted twenty-fold into 95 μL volumes of phosphate buffered saline (PBS, pH 7.4) in microtiter assay plates and allowed to reach equilibrium at room temperature for 24 h. The absorbance within each well of the plate was read spectrophotometrically at a wavelength of 620 nm. A precipitate forms when the maximum aqueous solubility level is reached. The value quoted is the highest concentration where the compound was in solution, that is, where no measurable precipitate was present.
-
The kinetic solubility of the compounds was measured using a turbidimetric method. A series of doubling dilutions of compounds were prepared in neat DMSO. Five microlitre samples were diluted twenty-fold into 95 μL volumes of phosphate buffered saline (PBS, pH 7.4) in microtiter assay plates and allowed to reach equilibrium at room temperature for 24 h. The absorbance within each well of the plate was read spectrophotometrically at a wavelength of 620 nm. A precipitate forms when the maximum aqueous solubility level is reached. The value quoted is the highest concentration where the compound was in solution, that is, where no measurable precipitate was present.
-
-
-
-
22
-
-
84891485219
-
-
International Patent WO 2012/142671.
-
Haydon, D.J. Czaplewski, L.G. Stokes, N.R. Davies, D. Collins, I. Palmer, J.T. Mitchell, J.P. Pitt G.R.W. Offermann, D. International Patent WO 2012/142671.
-
-
-
Haydon, D.J.1
Czaplewski, L.G.2
Stokes, N.R.3
Davies, D.4
Collins, I.5
Palmer, J.T.6
Mitchell, J.P.7
Pitt, G.R.W.8
Offermann, D.9
|